SGLT-2 inhibitors promising option for CVD prevention in diabetes patients regardless of NAFLD status: JAMA
South Korea: A recent study published in JAMA Network Open has highlighted the potential of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) as a promising option for preventing cardiovascular disease (CVD), irrespective of NAFLD status. In the population-based cohort study, GLP-1 receptor agonists and SGLT-2 inhibitor therapy were associated with reduced risk of major adverse cardiovascular events in […]